Key facts

Active Substance
Odronextamab
Therapeutic area
Oncology
Decision number
P/0197/2023
PIP number
EMEA-003149-PIP01-21-M01
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Treatment of mature B cell malignancies
Route(s) of administration
Intravenous use
Contact for public enquiries

Regeneron Ireland DAC

Tel. +1 9148 475385
E-mail: clinicaltrials@regeneron.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

Share this page